Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
[10] [16] The most frequent side-effects of tirzepatide include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain
Greater Weight Loss Was Linked to Lower Risk Compared with patients whose BMI fell by 0% to less than 5%, those who reduced their BMI by at least 15% had a 37% lower risk of osteoarthritis, a 30% lower risk of CKD, a 69% lower risk of OSA, and a 32% lower risk of heart failure
It was approved by the FDA in 2017 and grew sales by 60% in 2023 to DKK 96 billion
Liraglutide, injectable semaglutide, and dulaglutide have shown statistically significant reductions in major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors
Sources MOUNJARO (tirzepatide) Injection, for subcutaneous use (2022) Zepbound (tirzepatide) Injection, for subcutaneous use (2022) Tirzepatide Once Weekly for the Treatment of Obesity (June 4, 2022) Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (May 11, 2025)
US$ 26.11
US$ 29.82
US$ 24.72
US$ 20.17
US$ 23.58
US$ 23.30
US$ 20.59
